Skip navigation

Ready for some reading? In a 45 page option, Sam Glasscock of the Delaware Chancery Court slams Chinese reverse-merger scam Fuqi International (FUQI) and its Board of Directors. Some choice tidbits:

Plaintiff has pled facts with particularity that show that the Fuqi board has abdicated its responsibilities because the investigation has been left in limbo, with no progress, for several months. Under that view of the facts, Fuqi management is not entitled to the business judgment rule’s protections. Beyond that, Fuqi management has refused to pay for the professional  advisors—including auditors and legal counsel—of the Audit Committee performing the investigation. This lack of payment has thwarted what efforts could have been taken by the Audit Committee to investigate. To make matters worse, the independent directors, who could have conducted a meaningful investigation on behalf of the company, have resigned from their posts. Thus, the Plaintiff has alleged with particularity that the board has not only failed to move the investigation forward, but has also impeded that investigation. Nor does the record indicate that the investigation continues. It has been abandoned.

And yet the SEC still lets it trade.

Read the full decision here.

The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.

It was only a year ago when the Sefe, Inc. (SEFE) promotion was in full swing, and just weeks since Steve Kerr and Michael Quiel were convicted in case that illustrates how they used sham Swiss entities to mask share sales in their promotions.Shannon Kerr left the tattered remains of the company in March. But what has happened to the other players?

Read More »

Just a year ago Steve Kerr and Michael Quiel‘s Sefe, Inc. (SEFE) was in the middle of its hype-filled promotion to nearly $3.00. Today, SEFE would be lucky to see 3c, and Kerr and Quiel will be lucky to see daylight.

Read More »

While reading the series of stories in the Washington Post about the bribery scandal currently engulfing various Virginia politicians and shady Star Scientific (STSI), a documentary about a curious insect was playing on the television.

The North American cicada, Magicicada cassini, is famous for its distinctive chirp, and its life cycle, returning every 17 years. And so it is with some con men residing in the lower rungs of the stock market, reappearing every so often, and promoting their worthless shares with the same siren songs.

In January 1988 an article appeared in JAMA discussing Retin-A, a derivative of vitamin A, as a treatment for wrinkles. It set off an explosion in the use of Retin-A and a flurry of hype around some other, less well studied, products. The frenzy was so great that then-FDA commissioner Frank Young issued a warning to the public. An article in the LA Times, available here, explains:

Young said some unethical pharmacists, dermatologists and manufacturers were promoting and selling mixtures called Retin-A that actually contain different amounts of the active ingredient, retinoic acid.

Some manufacturers, he also said, are making bogus creams sold as Retin-A or as look-alike products that contain no retinoic acid…The FDA said it was “actively investigating a number of firms” promoting and selling wrinkle creams

Imagine the reaction at a small struggling firm in Massachusetts, called Spectra Pharmaceuticals (SPTPQ) when the JAMA article hit. For years Spectra, its Chairman and CEO, Dr. Al Maumanee of Johns Hopkins’ Wilmer Eye Institute, along with another scientist, Dr. Scheffer Tseng, had been studying their very own vitamin A derivative as an eye ointment first at Hopkins, and later at the Harvard-affiliated Massachusetts Eye and Ear Infirmary. But the studies were quite controversial.

According to a New York Times article, available here:

Read More »

The Kerr/Quiel trial has moved to the next stage. The jury has been charged and will return to the courtroom in Phoenix on the 9th of April to begin deliberations. From the docket:

Minute Entry – for proceedings held before Senior Judge James A Teilborg: Jury Trial as to Stephen M Kerr (01) and Michael Quiel (02) held on 4/3/2013.The Court instructs the jury as to the applicable law. Four (4) alternate jurors are selected. Jury to deliberate. Two (2) jury questions discussed and written responses returned to them. Jury at recess until 8:00 a.m., 4/9/2013. (Court Reporter David German.) Hearing held 9:02 AM to 4:35 PM.

Amazingly enough, during this whole ordeal the boys, with Humble Harold‘s help, have had time to tee up their latest creation….more to come.

Day after day FUQI shares trade, without the SEC doing a thing to protect investors from this long-running, obvious, Chinese con. Recall that FUQI has not filed a 10K since its 2008 report.

Yet the regulators are not always so reticent to act. In fact, the SEC has suspended trading in 13 companies since the beginning of 2013 due to “lack of current and accurate information.”

For example, on the first of March, the SEC halted trading in Southern USA Resources (SUSA):

Read More »

The court documents for the tax fraud trial of SEFE ringleaders Stephen Kerr and Michael Quiel, are becoming available. One, available here, indicates that Kerr and Quiel dealt with Adam Benowitz’s (here’s a pic) Vision Opportunity Capital Partners vehicle.

Vision is well known for its pumping of Chinese reverse merger junk, as well as for stuffing their listed vehicle, Vision Opportunity China Fund Ltd. (VOC on the AIM exchange, the UK’s answer to the Pink Sheets, now in liquidation) full of dreadful Chinese names. And known for being the subject of various probes. But who knew Adam and partner Randy Cohen, were also involved with the likes of Kerr and Quiel? Or K and Q with them? Small world indeed.

The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.

As expected, FUQI is still unable to file a 10K. In an NT10K filing last night, available here, they admit that not only can the company not produce the required documents by the normal deadline, they already know they will miss the 15 day extension period:

the Registrant is unable to timely file its Annual Report on Form 10- K for the year ended December 31 , 201 2 .   The Registrant will file its Annual Report on Form 10- K for the year ended December 31 , 201 2 as soon as it is able; however, the Registrant is not able to provide a reasonable estimate as to such filing at this time, which will not occur within the fifteenth calendar day after the prescribed due date for such report.

There is also a fascinating lawsuit in California between a FUQI stuckholder, Michael Patrick Kelly, and a former FUQI director and head of its Audit Committee, Victor Hollander.

Hollander, a US resident, is likely the only person affiliated with FUQI that can be properly served. Victor might want to make sure FUQI has been keeping up its D&O insurance. Here is an excerpt from the latest court filings:

Read More »

Back in October 2007, when the mania for all things speculative fraudulent and Chinese was at its peak, the investment banking powerhouses of Merriman Curhan, and Ford, along with (now jailed) Obama and Clinton fundraiser Hassan Nemazee’s Brean Murray, Carret & Co., brought an obscure Chinese jewelry company public. That company, Fuqi International (FUQI) unlike many disgraced Chinese stocks, still trades today.

Perhaps even more astounding is that the shares of Fuqi have risen from 61c at the start of the year, to around $1.50 earlier this week.

The question is why? FUQI has not filed a 10K for 2009, nor have they filed a 10K for 2010, nor 2011, nor (as of yet) 2012. Investors have no accurate public information. Well, almost none. Although the company cannot provide a set of reliable accounts, they did manage to disclose one small little item….

FUQI has received a nastygram from the SEC. According to an 8k filing on January 10th of this year:

Read More »

It was just under a year ago when we started to examine the wretched Sefe, Inc. (SEFE), the nearly vacant office occupying plaything of the Kerr and Quiel families. New BuyersStrike! readers can catch up here, here, here, and here.

So there was great sadness when the most recent SEFE 8k (available here) crossed our desks. According to the filing:

Read More »

Follow

Get every new post delivered to your Inbox.

Join 115 other followers